ipsogen JAK2 RGQ PCR Kit CE

• Reliable and sensitive quantification of JAK2 V617F

• An automated workflow from sample to result

• Compliance with EU IVD Directive 98/79/EC

• A master-mix with internal control

• Optimized for the Rotor-Gene Q MDx 5plex HRM

• Larsen’s primers in line with recent international recommendations (1)

The ipsogen JAK2 RGQ PCR Kit is an in vitro molecular diagnostic kit for real-time PCR on the Rotor-Gene Q MDx 5plex HRM instrument. The kit provides reagents optimized for reliable and sensitive detection, and clinically validated detection of the JAK2 V617F/G1849T mutation in genomic DNA extracted from peripheral blood of subjects with suspected myeloproliferative neoplasm (MPN).

To ensure improved sensitivity and reproducibility, the ipsogen JAK2 RGQ PCR Kit is optimized to detect the JAK2 V617F/G1849T mutation and uses prediluted plasmid standards, primers, and probe mixes in line with recent international technical recommendations (1). The sensitivity has a limit of detection (LOD) of 0.042%.

The first step is manual or automated QIAsymphony DSP extraction and determination of quality and quantity of genomic DNA. The second step is the amplification of DNA by real-time PCR, with all needed reagents provided in the kit. The ipsogen JAK2 RGQ PCR Kit detects and quantifies the JAK2 V617F/G1849T mutation on the Rotor-Gene Q MDx 5plex HRM instrument. Finally, the Rotor-Gene AssayManager software is used to interpret the results.

The ipsogen JAK2 RGQ PCR Kit for in vitro diagnostic use enables sensitive and reliable detection and quantification of the JAK2 V617F/G1849T mutation.

References:

1. Jovanovic, J.V., et al. (2013) Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27:2032.